

ASX ANNOUNCEMENT

26 August 2024

Register for Biome Australia's FY24 Overview Investor Webinar

- Biome Australia schedules FY24 Overview Webinar for Tuesday 3 September, 9.00am-9.45am AEST
- Register for the webinar [here](#)

Microbiome health company **Biome Australia Limited** (ASX: BIO) ('Biome' or 'the company') is pleased to invite investors and interested parties to the company's FY24 Overview Investor Webinar on Tuesday 3 September from 9.00am-9.45am AEST.

Hosted by Biome Australia Managing Director, Blair Vega Norfolk, our FY24 Investor Webinar will explore key results, including:

- Biome achieving positive EBITDA of \$287k for second half FY24 (adjusted for non-cash, share-based payment)
- Biome recording positive cash flow in Q2, Q3 and Q4
- Biome achieving ~\$13.01m in sales revenue, up 80%
- Q4 sales revenue reaching \$3.8m, up 88% vs PCP
- International sales reaching \$894k, up 95%
- Gross profit reaching ~\$7.91m, up 85%
- Gross margin exceeding 60%, up from ~59%
- Same-store sales in Biome's Australian pharmacy channel growing 75%
- Reporting \$2.7m in unrecognised future income tax benefit
- Biome securing high value, novel probiotic intellectual property

Please submit questions in advance to corporate@biomeaustralia.com. There will also be an opportunity during the webinar to submit questions to be answered live.

-ENDS-

Approved for release by the Biome Australia board of directors.

About Biome Australia Limited

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life, and make its products accessible to all.

Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership with some of the world's leading organisations in microbiome research and development, Biome produced several unique live biotherapeutic (probiotic) products with innovative delivery technologies that improve their stability and efficacy to create its flagship range of complementary medicines: Activated Probiotics[®].

Supported by clinical research, including randomised double-blind placebo-controlled trials, Activated Probiotics help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-only distribution, Biome is committed to educating health professionals on the newfound systemic health effects of the gut microbiota, helping them to provide innovative, evidence-based natural medicines for the management of some of humanity's most prevalent and chronic health concerns.

For more information visit: www.biomeaustralia.com

Investor Relations

Jo Power

+61 (3) 9017 5800

corporate@biomeaustralia.com

Media enquiries

media@activated.co



Forward looking statements

*This release may contain forward looking statements, including but not limited to projections, guidance on future revenues, earnings, other potential synergies and estimates and the future performance of Biome (**Forward Looking Statements**).*

Forward Looking Statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such Forward Looking Statements and any projections and assumptions on which these Forward Looking Statements are based. Such statements may assume the success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.

The Forward Looking Statements are based on information available to Biome as at the date of this release. Any Forward Looking Statements containing forward looking financial information provided in this release is for illustrative purposes only and is not represented as being indicative of Biome's views on its future financial condition and/or performance. The historic financial information for the September 2021 financial quarter and revenue figures for October and November 2021 have not been audited or reviewed by Biome's auditors. Such information should not be taken as a guide for future performance.

Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements contained in this release. Except as required by law or regulation (including the ASX Listing Rules), Biome does not undertake to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to the fairness, currency, accuracy, reliability or completeness of information in this release or the accuracy, likelihood of achievement or reasonableness of any Forward Looking Statements (or any event or results expressed or implied in any Forward Looking Statements) contained in, implied by, the information in this release or any part of it, or that this release contains all material information about Biome or which a prospective investor or purchaser may require in evaluating a possible investment in Biome or acquisition of securities in Biome.

Investors are strongly cautioned not to place undue reliance on Forward Looking Statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the Covid-19 pandemic.

